@unicancer @GETUG_Unicancer @UFR3S_ULille

@5_utr Great! The smartest trial in these patients on my opinion. @Icro_Meattini Unfortunately we weren't able to open in France. Congratulations again.

@drmikechao @seanmmcbride On our side we use 3mm all directions with MR Linac too, and a bit larger (as PACE) with cyberknife

@drmikechao @seanmmcbride In my opinion 3 mm margin or less requires MR Linac, but SBRT is safe with larger margins too

@jonas_willmann Very nice work! The radonc community has to stress the difficulty of financing these trials, most of them conducted at academic level. Phase II GETUG AFU 31 trial ongoing @GETUG_Unicancer

RT @acampsmalea: NRG Oncology International Consensus Contouring Atlas on Target Volumes and Dosing Strategies for Dose-Escalated Pancreati…

RT @Mat_Guc: SBRT for localized prostate cancer - the new SoC ? ! All questions to PACE-A and PACE-B studies answered by Prof. N. Van As…

RT @nickva1: Delighted to share the results of #PACE B trial, published in @NEJM today 5 fraction SBRT is non inferior to CRT! https://t.c…

RT @sbrtmemes: You know it's true #putthatcalculatoraway #gestalt

@Mat_Guc @UFR3S_ULille

RT @Larryferlazzo: Be humble. It’s good for learning and your relationships.

@abhiAsolanki @AnjaliSaripalli @AmarUKishan @BhanuPr92961213 Congratulations ! Very interesting and comprehensive work! Of little importance a typo in table 1, the Getug phase II dose is 36 Gy/6 fr @GETUG_Unicancer

RT @ESTRO_RT: 5-year outcomes from the hypo-FLAME trial, acute toxicity results from the PACE-C trial, and key findings from the STORM tria…

RT @ASCOPost: Cancer Mortality Among Adults With Learning Disabilities #cancer #LearningDisabilities #HealthEquity